Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1: In vitro and in vivo studies

被引：0
|
作者：
Deacon, CF
Knudsen, LB
Johansen, NL
Madsen, K
Holst, JJ
机构：
[1] UNIV COPENHAGEN,PANUM INST,DEPT MED PHYSIOL,DK-2200 COPENHAGEN,DENMARK
[2] NOVO NORDISK AS,MALOV,DENMARK
来源：
DIABETOLOGIA | 1997年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：492 / 492
页数：1
相关论文
共 50 条
  • [21] Modulation of glucagon-like peptide-1 release by berberine: In vivo and in vitro studies
    Yu, Yunli
    Liu, Li
    Wang, Xinting
    Liu, Xiang
    Liu, Xiaodong
    Xie, Lin
    Wang, Guangji
    [J]. BIOCHEMICAL PHARMACOLOGY, 2010, 79 (07) : 1000 - 1006
  • [22] Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs
    Mentlein, R
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (01) : 57 - 64
  • [23] Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance
    Itou, Minoru
    Kawaguchi, Takumi
    Taniguchi, Eitaro
    Sumie, Shuji
    Oriishi, Tetsuharu
    Mitsuyama, Keiichi
    Tsuruta, Osamu
    Ueno, Takato
    Sata, Michio
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (02) : 244 - 251
  • [24] The Expression of Glucagon-Like Peptide-1 Receptor and Dipeptidyl Peptidase-IV in Neuroendocrine Neoplasms of the Pancreas and Gastrointestinal Tract
    Wada, Ryuichi
    Yagihashi, Soroku
    [J]. ENDOCRINE PATHOLOGY, 2014, 25 (04) : 390 - 396
  • [25] The Expression of Glucagon-Like Peptide-1 Receptor and Dipeptidyl Peptidase-IV in Neuroendocrine Neoplasms of the Pancreas and Gastrointestinal Tract
    Ryuichi Wada
    Soroku Yagihashi
    [J]. Endocrine Pathology, 2014, 25 : 390 - 396
  • [26] Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension
    Jingjing Wang
    Min Yu
    Jian Xu
    Yusheng Cheng
    Xiang Li
    Guihong Wei
    Hong Wang
    Hui Kong
    Weiping Xie
    [J]. Journal of Biomedical Science, 26
  • [27] Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension
    Wang, Jingjing
    Yu, Min
    Xu, Jian
    Cheng, Yusheng
    Li, Xiang
    Wei, Guihong
    Wang, Hong
    Kong, Hui
    Xie, Weiping
    [J]. JOURNAL OF BIOMEDICAL SCIENCE, 2019, 26 (1)
  • [28] Synthesis and Biological Activity Studies of Glucagon-Like Peptide-1 Analogues
    Chi, Yu-Shi
    Huang, Wen-Long
    Zhang, Hui-Bin
    Zhou, Jin-Pei
    Zhou, Ying-Hong
    Ni, Shuai-Jian
    Qian, Hai
    [J]. CHINESE JOURNAL OF ORGANIC CHEMISTRY, 2008, 28 (11) : 1925 - 1931
  • [29] Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier
    Zhao, Dandan
    Zhao, Shaoqian
    Wang, Xiao
    Su, Mingbo
    Liu, Wen
    Ma, Qinyun
    Hong, Jie
    Gu, Weiqiong
    Li, Jingya
    Liu, Ruixin
    Ning, Guang
    Wang, Jiqiu
    Zhang, Yifei
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2018, 9
  • [30] Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1
    Duffy, Nicola A.
    Green, Brian D.
    Irwin, Nigel
    Gault, Victor A.
    McKillop, Aine M.
    O'Harte, Finbarr P. M.
    Flatt, Peter R.
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 568 (1-3) : 278 - 286
12345